Quidel Corporation (QDEL) versus Neovasc (NVCN) Head-To-Head Contrast

Neovasc (NASDAQ: NVCN) and Quidel Corporation (NASDAQ:QDEL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, institutional ownership, valuation and profitability.

Valuation & Earnings

This table compares Neovasc and Quidel Corporation’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Neovasc $9.51 million 6.97 -$86.49 million ($0.14) -6.00
Quidel Corporation $191.60 million 6.74 -$13.80 million ($0.15) -253.38

Quidel Corporation has higher revenue and earnings than Neovasc. Quidel Corporation is trading at a lower price-to-earnings ratio than Neovasc, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Neovasc and Quidel Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Neovasc -68.34% -58.08% 23.23%
Quidel Corporation -2.33% -2.36% -1.25%

Volatility and Risk

Neovasc has a beta of 0.27, meaning that its stock price is 73% less volatile than the S&P 500. Comparatively, Quidel Corporation has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500.

Institutional and Insider Ownership

19.4% of Neovasc shares are owned by institutional investors. Comparatively, 84.4% of Quidel Corporation shares are owned by institutional investors. 22.0% of Quidel Corporation shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations for Neovasc and Quidel Corporation, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neovasc 0 0 3 0 3.00
Quidel Corporation 0 1 5 0 2.83

Neovasc presently has a consensus target price of $6.33, indicating a potential upside of 653.97%. Quidel Corporation has a consensus target price of $48.50, indicating a potential upside of 27.60%. Given Neovasc’s stronger consensus rating and higher possible upside, equities analysts clearly believe Neovasc is more favorable than Quidel Corporation.

Summary

Quidel Corporation beats Neovasc on 8 of the 13 factors compared between the two stocks.

Neovasc Company Profile

Neovasc Inc. (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company’s segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products. The Tiara is in preclinical/early clinical stage development to provide a minimally invasive transcatheter device for patients experiencing mitral regurgitation (MR) as a result of mitral heart valve disease. The Reducer is an hourglass-shaped, balloon-expandable, stainless steel, bare metal device, which is implanted in the coronary sinus, creating a restriction in venous outflow from the myocardium (the muscular layer of the heart wall). Neovasc produces Peripatch, a biological tissue product that is manufactured from pericardium.

Quidel Corporation Company Profile

Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers. Its diagnostic solutions aid in the detection and diagnosis of critical diseases and other medical conditions, including infectious diseases, women’s health, gastrointestinal diseases, autoimmune diseases, bone health and thyroid diseases. The Company provides diagnostic testing solutions under various brand names, including Quidel, QuickVue, QuickVue+, MicroVue, FreshCells, D3 FastPoint, Super E-Mix, ELVIS, Sofia, Quidel Molecular, Amplivue, Lyra and Thyretain.

Receive News & Ratings for Neovasc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply